premature ovarian insufficiency (POI)/ premature ovarian failure (POF)
Conditions
Interventions
Intervention group:laparoscopic in vivo activation of ovarian cortex
Sponsors
Guangdong Second Provincial General Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Premature ovarian failure (POF): (1) Less than 40 years old; (2) Primary or secondary amenorrhea > for 4 months; (3) FSH > 40IU/L at least once; (4) Accompanied by hot flashes, sweating, mood swings and other estrogen reduction symptoms of menopause; (5) Good function of heart, liver, kidney and blood coagulation, no history of internal and surgical diseases or malignant tumors; (6) The chromosomes are normal and there are no genetic diseases; (7) The patient and/her family members voluntarily participate in the trial and sign the informed consent form. They have fertility requirements and plan to perform Assisted Reproduction Technology. 2. Patients with premature ovarian insufficiency (POI): (1) Less than 40 years old; (2) The number of basic follicles in the ovarian was less than 4, and 25U/L<= FSH <= 40 IU/L, at least one test result (3) No oocytes were obtained in previous IVF cycles or no embryos were available although oocytes were obtained; (4) Good function of heart, liver, kidney and blood coagulation, no history of internal and surgical diseases or malignant tumors; (5) The chromosomes are normal and there are no genetic diseases; (6) The patient and her family members voluntarily participate in the trial and sign the informed consent form. They have fertility requirements and plan to perform Assisted Reproduction Technology.
Exclusion criteria
Exclusion criteria: 1. Definite chromosomal abnormalities or serious genetic diseases; 2. Contraindications to laparoscopic surgery; 3. Pregnant or nursing patients; 4. Participated in other clinical trials in the last 3 months; 5. Lack of legal capacity or limited legal capacity; 6. Any other conditions in which the investigator considers it is inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical pregnancy rate;Cumulative live birth rate;Ovarian reserve function recovery rate (At any time point post-treatment, serum Anti-Müllerian Hormone (AMH) levels increase from baseline AND baseline Antral Follicle Count (AFC) increases by >= 1); | — |
Secondary
| Measure | Time frame |
|---|---|
| Perimenopausal symptom score; | — |
Countries
China
Contacts
Public ContactOu Xianghong
Guangdong Second Provincial General Hospital
Outcome results
None listed